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Abstract 
Background: MicroRNAs (miRNAs) play pivotal roles in the development of various cancer types, including cervical 
cancer.
Methods and results: In this study, we showed that miR‑519d, a miRNA within the chromosome 19 miRNA cluster, 
was significantly upregulated in cervical cancer tissues, compared with non‑tumorous cervical samples. Suppression 
of miR‑519d markedly attenuated the migration and invasion of HeLa and SiHa cervical cancer cells. Additionally, miR‑
519d inhibited the apoptosis of cervical cancer cells, and the proliferation of cervical cancer cells was also affected 
following transfection of miR‑519d inhibitor. Moreover, we identified Smad7 to be a novel target of miR‑519d in cervi‑
cal cancer cells. MiR‑519d matched the 3′‑UTR of Smad7 mRNA. Transfection with miR‑519d mimics led to apparent 
downregulation of Smad7 both at the mRNA and protein levels. Luciferase reporter analysis revealed that miR‑519d 
reduced the luciferase activity of Smad7 mRNA 3′‑UTR through matching site‑dependent manner. And more notably, 
suppression of Smad7 remarkably restored the migration and invasion of miR‑519d‑depleted cervical cancer cells.
Conclusion: Taken together, these findings implicated that miR‑519d promoted the progression and metastasis of 
cervical cancer through targeting Smad7.
Keywords: MiR‑519d, Cervical cancer, Metastasis, Smad7, Proliferation
© 2016 Zhou et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Cervical cancer represents the third most frequent cancer 
and the fourth leading cause of cancer-related morality 
in women worldwide. According to recent global can-
cer statistics, it is estimated that there are approximate 
530,000 new cervical cancer cases annually, and 275,000 
cervical cancer-related deaths [1]. In addition, the prog-
nosis of cervical cancer remains unsatisfactory, with a 
5  year overall survival of approximate 36.5  % in United 
States [2]. Therefore, cervical cancer remains a signifi-
cant threat to female health. Mounting studies indicated 
that distant metastasis is a key determinant that predicts 
the survival of cervical cancer patients. Patients with 
metastatic cervical cancer (mCC) have markedly wors-
ened prognosis, compared with non-mCC patients [3]. 
However, the molecular mechanism underlying cervical 
cancer invasion and metastasis remains largely unclear, 
limiting the therapeutic options in the management of 
this deadly disease.
Cervical cancer metastasis involves complex molecular 
mechanisms. A variety of signaling pathways, including 
TGF-β/Smads, Wnt/β-catenin and JAK/STATs pathways, 
have been implicated in the regulation of cervical cancer 
metastasis and invasion. Serving as a master regulator 
of cell motility and migration, TGF-β/Smads signaling 
has been extensively documented to play a pivotal role 
in determining the metastasis of various cancer types, 
including cervical cancer. It was reported that hyperac-
tivation of TGF-β signaling was associated with lymph 
node metastasis in cervical cancer [4, 5]. TGF-β pathway 
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mainly signals through Smad proteins. The TGF-β recep-
tors directly phosphorylate receptor-activated Smads 
(R-Smads) to trigger their nuclear translocation. Sub-
sequently, nuclear translocated R-Smads interact with 
Smad4 to form Smad complex and direct the transcrip-
tion of target genes through their transcription factor 
activities. In addition to R-Smads and Smad4, Smad6 and 
Smad7 serve as inhibitory Smads (I-Smads) to attenuate 
the activity of TGF-β signaling. Studies have indicated 
that overexpression of Smad7 impaired the metasta-
sis and invasion of tumor cells via negative regulation 
of TGF-β [6, 7]. It was reported that Smad7 was rarely 
mutated in human cervical cancer tissues [8]. However, 
it remains unclear whether posttranscriptional regulation 
of Smad7 may contribute to the development of cervical 
cancer.
MicroRNAs (miRNAs) are a conserved class of 22  bp 
long non-coding RNAs that have been discovered over 
a decade ago. Since their discoveries, numerous studies 
have highlighted critical involvement of miRNAs in the 
regulation of gene expression and cellular signaling trans-
duction [9]. miRNAs primarily regulate gene expres-
sion through directly binding to the matched sites of 
mRNAs and triggering rapid decay of target mRNAs. In 
this way, miRNAs play important roles in diverse biologi-
cal processes, such as organism development, immune 
regulation and tumorigenesis [10, 11]. Currently, many 
miRNAs have been documented to possess oncogenic 
or tumor-suppressive properties. For example, miR-21 
has been repeatedly reported to facilitate tumor progres-
sion through targeting assorted tumor-suppressors, such 
as Bcl-2, PDCD4 and PTEN [12–14]. MiR-519d triggers 
multiple gene targets, including p21, PTEN, AKT3 and 
TIMP2 to potentiate HCC development [15]. Xiaoxia 
Hu et al. reported that miR-200a and miR-9 might exert 
important regulatory roles in cervical cancer develop-
ment and metastasis, and potentially served as prog-
nostic indicators of cervical cancer patients’ survival. 
However, to date, the regulatory role of miRNAs in the 
development and metastasis of cervical cancer remains 
poorly documented [16].
Given the information above, we investigated the miR-
NAs that potentially regulates the development and 
metastasis of cervical cancer. We identified that miR-
519d was highly expressed in cervical cancer specimens. 
In addition, we showed that miR-519d facilitated cervi-
cal cancer proliferation, migration and invasion in vitro. 
Moreover, we identified Smad7 to be a novel target gene 
of miR-519d. Depletion of Smad7 regained the migration 
and invasion of cervical cancer cells following miR-519d 
inhibition. Our findings implied that high expression of 
miR-519d may contribute to the development of cervical 
cancer through targeting Smad7, providing novel insight 




Cervical cancer tissues and adjacent normal tissues 
were obtained from 20 patients, who underwent cer-
vical surgical resection without preoperative systemic 
therapy at Nanfang Hospital of Southern Medical Uni-
versity between September 2013 and January 2015. The 
major pathologic variables were obtained and recorded 
before surgical resection. After surgical removal, the tis-
sues were immediately frozen using liquid nitrogen. All 
human tissues were collected in accordance with proto-
cols approved by the Ethics Committee of the Nanfang 
Hospital of Southern Medical University.
Cell culture, construct and transfection
HeLa and SiHa cells were obtained from Shanghai Insti-
tute of Cell Biology, Academic Sinica, and cultured in 
high-glucose DMEM (Invitrogen) supplemented with 
10  % fetal bovine serum (Hyclone, South America) at 
37  °C and 5  % CO2. Smad7 shRNA was obtained from 
Genechem company (Shanghai, China). The miR-519d 
mimics and inhibitor were obtained from Invitrogen 
(Carlsbad, CA). The transfection of miR-519d mimics, 
inhibitor and shSmad7 oligo was performed using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s instruments.
MiRNA extraction, reverse transcription and real‑time PCR 
detection
The total RNA was extracted using Trizol reagent, and 
reversely transcribed into cDNA. Real-time PCR detec-
tion of miR-519d was conducted as reported by Franc-
esca Fornari et  al. [15]. The primers used for RT-PCR 
detection included: miR-519d, 5′-ACA CTC CAG CTG 
GGC AAA GTG CCT CCC T-3′, and 5′-CTC AAC TGG 
TGT CGT GGA-3′; U6, 5′-CTC GCT TCG GCA GCA 
CA-3′, and 5′-AAC GCT TCA CGA ATT TGC GT-3′; 
Smad7, 5′-CTC GGT GAA ACC CGT CCA T-3′, and 
5′-GAG CAA ATC CTT TCC GAC CAG-3′; GAPDH, 
5′-CGG AGT CAA CGG ATT TGG TCG TAT-3′ and 
5′-AGC CTT CTC CAT GGT GGT GAA GAC-3′.
Cell migration and invasion assay
For cell migration assay, 5 × 104 HeLa or SiHa cells were 
placed into the upper part of transwell chamber contain-
ing a non-coated membrane in 200 μl serum-free DMEM 
medium. As to cell invasion assay, 5 × 104 HeLa or SiHa 
cells were seeded into the upper chamber of coated with 
40 μl of 2 mg/ml Matrigel (BD Matrigel™ matrix; BD Bio-
science, Heidelberg, Germany). Six hundred micro-liters 
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DMEM medium containing 20  % FBS was added into 
the lower part of the chamber. After incubation for 24 h, 
the membranes were stained using 2 % crystal violet for 
15  min. The cells that traveled through the membranes 
were examined using a digital light microscope. Each 
experiment has been repeated at least three times.
Western blot analysis
Cervical cancer samples and cells were homogenized 
using a lysis buffer containing 50  mM Tirs-Cl, pH 7.4, 
120 mM NaCl, 1 % NP-40, 0.2 % SDS, 1 mM EDTA and 
complete protease inhibitor cocktail (Roche Diagnos-
tics, Basel, Switzerland), and centrifuged for 20  min at 
13,000g, 4 °C. The protein concentration of cell lysate was 
analyzed using BCA protein assay kit (Bio-Rad, Hercules, 
CA). The protein samples were separated by SDS-PAGE 
and transferred into PVDF membranes. The membranes 
were blocked using blocking solution (150  mM NaCl, 
20 mM Tris, pH 8.0, 0.05 % Tween-20, 5 % non-fat milk). 
Thereafter, the membranes were incubated with the indi-
cated primary antibodies: rabbit polyclonal anti-Smad7 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) 
and mouse monoclonal anti-GAPDH antibody (TA-08, 
Zhongshan Golden Bridge, Beijing, China). Second-
ary antibody incubation was conducted using horserad-
ish peroxidase (HRP)-conjugated goat anti-mouse and 
anti-rabbit antibodies. The protein bands were visual-
ized using ECL methods according to the manufacturer’s 
instruments (Zhongshan Golden Bridge, Beijing, China). 
The densities of protein bands were relatively quanti-
fied using ImageJ software (WS Rasband, ImageJ, NIH, 
Bethesda, MD). All experiments have been indepen-
dently performed for three times.
Flow cytometric analysis
HeLa and SiHa cells were transfected with NC miRNA, 
miR-519d inhibitor or shSmad7 oligo. Twenty-four hours 
after transfection, cells were exposed to 10 μM 5-fluoro-
uracil (5-FU; Sigma, St Louis, MO) for an additional 24 h. 
Next, cells were harvested and flow cytometric analysis of 
cell apoptosis was carried out using an Annexin V-FITC/
PI kit (BD PharMingen, San Diego, CA, USA) in accord-
ance with the manufacturer’s instruments.
MTT cell proliferation assay
MTT assay was performed using a protocol similarly to 
a previous report [17]. Briefly, HeLa and SiHa cells were 
plated into 96-well plates at a cell density of 2 × 103 cells 
per well. At the indicated time points, cells were incu-
bated with 20  μM MTT reagent in DMEM complete 
medium for 4  h. Thereafter, the medium was removed 
and 200  μl DMSO was added to incubate for an addi-
tional 20  min. The plate was read at 570  nm with a 
reference wavelength of 630  nm using an ELX Ultra 
Microplate Reader (Bio-tek, Winooski, VT, USA).
Luciferase reporter assay
The 3′-UTR of Smad7 mRNA was subcloned into a Psi-
CHECK2 luciferase reporter construct. The predicted 
miR-519d-binding site was mutated using overlap exten-
sion PCR to generate the Smad7mt-Luc construct. HeLa 
and SiHa cells were transfected with NC miRNA or 
miR-519d, together with Smad7wt-Luc or Smad7mt-
Luc construct. Forty-eight hours after transfection, dual 
luciferase reporter assay was performed using Dual-lucif-
erase reporter assay system (Promega, Madison, WI) in 
accordance with the manufacturer’s instruments.
Statistical analysis
Statistical analyses were carried out using the SPSS 
17.0 software package. Two-way analysis of variance 
(ANOVA), followed by a Student–Newman–Keuls post 
hoc test, was performed for the comparison between dif-
ferent groups of data. Student’s t test was applied when 
appropriate. P < 0.05 was considered statistically signifi-
cant. All values were expressed as mean ± SE.
Results
Inhibition of miR‑519d suppressed the proliferation 
and viability of cervical cancer cells
In order to clarify the involvement of miR-519d in cer-
vical cancer development and progression, miR-519d 
inhibitor was employed to investigate the impact of 
miR-519d inhibition on the physiology of cervical can-
cer cells. After transfection with miR-519d inhibitor, the 
cellular level of miR-519d was first determined using 
Real-time PCR analysis, the results showed that miR-
519d expression level exhibited a significant decrease 
after transfection with miR-519d inhibitor (Fig.  1a, b). 
And then, the impact of miR-519d inhibitor on cell pro-
liferation and viability was analyzed. As shown in Fig. 1c 
and d, transfected with miR-519d inhibitor significantly 
attenuated the proliferation of HeLa and SiHa cervical 
cancer cells. Furthermore, HeLa and SiHa cells were 
transfected with NC miRNA or miR-519d inhibitor, 
and then exposed to 10  μM 5-fluorouracil (5-FU) for 
24 h. The cells were subjected to Annexin/PI apoptotic 
analysis, which showed that suppression of miR-519d 
distinctively augmented the proportion of apoptotic 
cells both in HeLa and SiHa cells (Fig. 1e, f ). Moreover, 
flow cytometrical analysis indicated that transfection of 
miR-519d inhibitor augmented the proportion of cells 
in G1 phase, whereas reduced cells in S phase (Fig. 1g). 
These findings indicated that miR-519d might promote 
the proliferation and chemoresistance of cervical cancer 
cells.
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Fig. 1 The impact of miR‑519d inhibition on the proliferation and viability of cervical cancer cells. a, b The efficiency of miR‑519d inhibitor has 
been detected by real‑time PCR in Hela and SiHa cells (*P < 0.05). c, d HeLa and SiHa were subjected to MTT assay at different time periods (24, 48, 
72 and 96 h) following transfection with NC miRNA or miR‑519d inhibitor (*P < 0.05). e Annexin/PI apoptotic assay was performed to determine 
the proportion of apoptotic cells in HeLa and SiHa following transfection with NC miRNA or miR‑519d inhibitor, along with 10 μM 5‑FU treatment. 
f Statistical analysis of the proportion of apoptotic cells in the indicated groups (*P < 0.05). g Flow cytometrical analysis of cell cycle distribution of 
HeLa and SiHa cells following transfection with NC miRNA or miR‑519d inhibitor (*P < 0.05)
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Inhibition of miR‑519d attenuated the migration 
and invasion of cervical cancer cells
Next, the migration of HeLa and SiHa cells was analyzed 
using transwell assay. Transfection of miR-519d inhibi-
tor markedly impaired the migrating capacities of both 
HeLa and SiHa cells (Fig.  2a). The number of migrated 
cervical cancer cells declined significantly following 
miR-519d inhibition (Fig. 2b). Moreover, the influence of 
miR-519d on the invasion of cervical cancer was evalu-
ated using matrigel transwell assay. As predicted, trans-
fection of miR-519d inhibitor reduced the number of 
cells invading through matrigel both in HeLa and SiHa 
cells (Fig. 2c, d).
Smad7 is a novel target gene of miR‑519d in cervical 
cancer cells
Because miRNAs mainly modulate protein expres-
sion through direct RNA binding and decay, we were 
interested in the potential target genes involved in the 
tumorigenic role of miR-519d in cervical cancer. Using 
four independent miRNA target prediction softwares 
(miRanda, miRDB, miRWalk RNA22 and Targetscan), 
we identified that Smad7, a negative regulator of TGF-β 
signaling, as a novel candidate target gene of miR-
519d. Next, we determined whether miR-519d might 
mediate the decay of Smad7 mRNA via direct asso-
ciation with mRNA 3′-UTR. To this end, the 3′-UTR of 
Fig. 2 Transfection of miR‑519d inhibitor restrained the migration and invasion of HeLa and SiHa cervical cancer cells. a Determining the impact of 
miR‑519d inhibitor on the migration of HeLa and SiHa cells using transwell assay. The representative images showed that miR‑519d inhibitor signifi‑
cantly attenuated the migration of HeLa and SiHa cells. b Quantitative analysis of the number of migrated cells in NC miRNA and miR‑519d inhibitor 
groups (*P < 0.05). c Matrigel transwell analysis of the influence of miR‑519d on the invasion of HeLa and SiHa cells. The representative images 
showed that miR‑519d inhibitor significantly reduced the invasion of HeLa and SiHa cells. d Quantitative analysis of the number of cells invading 
through matrigel in NC miRNA and miR‑519d inhibitor groups (*P < 0.05)
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Smad7 mRNA was subcloned into Psi-CHECK2 lucif-
erase reporter construct (designated as Smad7wt-Luc) 
(Fig.  3a). In addition, a mutant form of Smad7wt-Luc 
construct was generated through mutating the binding 
site of miR-519d (designated as Smad7mt-Luc) (Fig. 3a). 
Thereafter, the Smad7wt-Luc or Smad7mt-Luc construct 
was co-transfected with control miRNA or miR-519d 
into HeLa and SiHa cells. Forty-eight hours after trans-
fection, the luciferase activity was assessed. As shown in 
Fig. 3b, miR-519d remarkably down-regulated the activ-
ity of Smad7wt-Luc both in HeLa and SiHa cells. While 
the activity of Smad7mt-Luc both in HeLa and SiHa 
cells were unchanged (Fig.  3b). Then, overexpression 
of miR-519d significantly attenuated the expression 
of Smad7 mRNA both in HeLa and SiHa cells (Fig.  3c). 
Likewise, the protein level of Smad7 also declined fol-
lowing miR-519d overexpression (Fig. 3d). These findings 
proved that the predicted binding site of Smad7 mRNA 
3′-UTR played an essential role in miR-519d-modulated 
Smad7 expression, implicating that Smad7 is a direct tar-
get of miR-519d in cervical cancer.
Interference of Smad7 restored miR‑519d‑mediated 
cervical cancer invasion and viability
In the next step, we analyzed the involvement of Smad7 
in the tumor-promoting role of miR-519d in cervical 
Fig. 3 Smad7 is a novel target gene of miR‑519d in cervical cancer. a Potential binding pattern of miR‑519d to the 3′‑UTR of Smad7 mRNA and 
the construct information of mutant Smad7 3′‑UTR. b Firefly luciferase reporter assay through co‑transfecting Smad7wt‑Luc or Smad7mt‑Luc with 
a Renilla luciferase control plasmid (pRL‑TK), along with NC miRNA or miR‑519d mimics. Shown were relative luciferase acitivities normalized to NC 
miRNA group (*P < 0.05). c Quantitative RT‑PCR analysis of Smad7 mRNA in cervical cancer cells after transfection with NC miRNA or miR‑519d mim‑
ics (*P < 0.05). d Western blot analysis revealed that the protein level of Smad7 was markedly reduced following miR‑519d overexpression in HeLa 
and SiHa cells
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cancer. To this end, the Smad7-targeting shRNA oligo 
were employed to deplete endogenous Smad7 in cer-
vical cancer cells. NC, miR-519d inhibitor and Smad7 
shRNA oligo were transfected independently or simulta-
neously into cervical cancer cells. Real-time PCR analy-
sis revealed that Smad7 shRNA oligo transfection group 
showed a significance reduced level of Smad7 mRNA 
compared with NC group. While the miR-519d inhibi-
tor transfection group exhibited the highest expression 
level of Smad7 mRNA. And the Smad7 mRNA expres-
sion level of co-transfection group was below than NC 
group but higher than Smad7 shRNA oligo transfection 
group (Fig.  4a, b). In keeping with the real-time PCR 
results, western blot analysis displayed a similar vary-
ing tendency (Fig. 4c, d). The impact of Smad7 depletion 
on miR-519d-mediated cell viability was investigated. 
Then, we found that HeLa and SiHa cells exhibited dis-
tinct responses to Smad7, with regard to miR-519d-me-
diated anti-apoptotic effect. Whereas depletion of Smad7 
restored the apoptotic response in miR-519d-inhibit-
ing SiHa cells, HeLa cells did not display any difference 
in apoptotic rate in response to Smad7 interference 
(Fig.  4e–g). These findings inferred that other target 
genes probably played a regulatory role in miR-519d-trig-
gered anti-apoptotic effect in HeLa cells.
Furthermore, we analyzed the involvement of Smad7 in 
miR-519d-mediated cervical cancer migration and inva-
sion. To this end, NC or miR-519d inhibitor plus with or 
without shSmad7 oligo were co-transfected into HeLa 
and SiHa cells. As shown in Fig.  5a and b, depletion of 
Smad7 by transfection of shSmad7 oligo significantly pro-
mote the proliferation of HeLa and SiHa cervical cancer 
cells compared with NC group. However, the prolifera-
tion of HeLa and SiHa cervical cancer cells were restored 
after co-transfection with miR-519d inhibitor. Further-
more, flow cytometrical analysis indicated that inhibiting 
Smad7 expression reduced the proportion of cells in G1 
phase, whereas increased cells in S phase (Fig. 5c). And 
depletion of Smad7 induced an approximate 50 % upreg-
ulation of cell migration both in HeLa and SiHa cells 
(Fig.  6a–c). Likewise, matrigel transwell assay revealed 
that transfection of shSmad7 oligo resulted in compara-
ble increase of cervical cancer cell invasion (Fig.  6d–f). 
Taken together, our findings conceivably validated that 
Smad7 potentially played an important role in miR-
519d-mediated cervical cancer invasion and progression.
MiR‑519d was highly expressed in cervical cancer 
specimens
MiR-519d was reportedly associated with the metastasis 
of osteosarcoma [18], and based on the above results, we 
confirmed that miR-519d significantly affected the pro-
gression and metastasis of cervical cancer through direct 
targeting Smad7. However, it was not clear whether 
miR-519d is highly expressed in cervical cancer tissues. 
In order to solve this problem, Real-time PCR was per-
formed to check the differential expression of miR-519d 
between cervical cancer tissues and adjacent normal 
tissues. The results was shown in Fig.  7a, miR-519d is 
evidently upregulated in cervical cancer specimens. In 
addition, the expression of Smad7, a potential target of 
miR-519d, was also examined between cervical cancer 
and adjacent non-tumorous tissues, which found that 
Smad7 was downregulated in cervical cancer samples, 
compared with non-tumorous tissues (Fig. 7b). This piece 
of data verified that upregulated expression of miR-519d 
may contribute to the progression of cervical cancer.
Discussion
Increasing evidence indicated that miRNAs played an 
integral roles in cervical tumorigenesis. Through screen-
ing tissue miRNA expression, a variety of miRNAs have 
been reported to be critically implicated in cervical 
cancer development and progression [19]. Smad7 is a 
critical inhibitor of TGF-β signaling pathway, which was 
reported to be expressed in tumor cells of numerous can-
cer types, including cervical cancer [20, 21]. In the pre-
sent study, we for the first time showed that miR-519d 
was obviously upregulated in cervical cancer samples. 
Moreover, we found that miR-519d promoted the migra-
tion and invasion of cervical cancer cells. Additionally, 
miR-519d exerted an inhibitory role in the apoptosis of 
cervical cancer cells. Finally, we identified that Smad7 
was a novel miR-519d target gene, and played a crucial 
role in miR-519d mediated tumor-facilitating effect in 
cervical cancer. These results uncovered a novel mecha-
nism through which miR-519d promoted the viabil-
ity and invasion of cervical cancer cells via suppressing 
Smad7 expression.
The importance of miRNAs in human tumor develop-
ment has attracted significant attention in recent years. 
MiR-519d is located at chromosome 19 cluster, and was 
initially reported to target Ki-67, a proliferation marker 
protein, and suppress the in vitro growth of hepatocellu-
lar carcinoma cells [22]. However, later studies implicated 
that miR-519d also targeted several tumor suppressors, 
including CDKN1A/p21, PTEN and TIMP2, and thus 
potentially exerted oncogenic property in hepatocellu-
lar carcinoma development [15]. Indeed, miR-519d has 
been reportedly overexpressed in assorted human can-
cers, such as hepatocellular carcinoma, breast cancer, 
gastric cancer and clear cell renal cell carcinoma et  al. 
[15, 23–26]. Accordingly, overexpression of miR-519d 
facilitated the proliferation, invasion and attenuated the 
apoptosis of cancer cells. However, notably, miR-519d 
exhibited remarkable downregulation in ovarian cancer 
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Fig. 4 The effect of Smad7 depletion on miR‑519d‑mediated cervical cancer chemoresistance. a, b Real‑time PCR analysis of Smad7 mRNA expres‑
sion was performed after transfection of miR‑519d inhibitor and Smad7 shRNA independently or simultaneously, the results were normalized to NC 
group. GAPDH was used as internal control (*P < 0.05). c, d Western blot analysis was performed to verify the protein expression level of Smad7 in 
the indicated groups. e After cell transfection and 5‑FU treatment, Annexin V/PI analysis was performed to determine cell apoptosis in the indicated 
groups. f, g Statistical analysis of the proportion of apoptotic cells compared with NC group (*P < 0.05)
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[27]. In this respect, the biological significance of miR-
519d promote cervical cancer development and progres-
sion remains virtually unknown. Our findings implicated 
that upregulated expression of miR-519d might contrib-
ute to cervical tumorigenesis via targeting Smad7, while 
depletion of Smad7 abrogated the influence of miR-519d 
on cervical cancer migration and invasion. Therefore, the 
precise role of miR-519d may vary between different can-
cer types, which may be attributed to different major tar-
gets in these cancers.
Metastasis represents the single most important prog-
nostic factor predicting survival in cervical cancer [28]. 
However, the molecular mechanism underlying cervical 
cancer metastasis remains poorly understood. Several 
lines of studies indicated that TGF-β/Smads signaling 
played a vital importance in facilitating the metastasis 
of cervical cancer [4, 29, 30]. Therefore, it is important 
to clarify the mechanism underlying TGF-β hyperacti-
vation in mCC. Serving as a potent inhibitor of TGF-β 
signaling, Smad7 is also a direct target of TGF-β/Smads 
pathway [31]. Thus, TGF-β-directed Smad7 expression 
functions as a negative feedback loop to prevent uncon-
trolled activation of TGF-β signaling. Low expression 
of Smad7 was associated with enhanced metastasis 
and poor prognosis in pancreatic cancer [32]. Consist-
ent with these data, stable expression of Smad7 impairs 
tumor metastasis in vivo [6, 7]. However, the expression 
pattern and pathological significance of Smad7 in cervi-
cal cancer remains to be clarified. Interestingly, recent 
reports indicated that several miRNAs induced tumor 
metastasis through targeting Smad7 [33–36]. These find-
ings suggested that miRNAs played an integral role in the 
regulation of Smad7 expression in tumor cells. Coincid-
ing with this hypothesis, we found that miR-519d directly 
targeted Smad7 in cervical cancer cells. Suppression 
of miR-519d augmented Smad7 expression, leading to 
attenuated capacity of cervical cancer invasion. In addi-
tion to cell migration and invasion, our findings inferred 
that miR-519d regulated the apoptosis of cervical cancer 
cells. In this regard, we proposed that miR-519d might 
target other potential genes to regulate cervical cancer 
apoptosis, because transfection of shSmad7 oligo did not 
Fig. 5 Depletion of Smad7 restored the cell proliferation and the cell cycle is disrupted in cervical cancer cells under miR‑519d inhibition. a, b The 
proliferation rate of HeLa and SiHa cells were detected through MTT assay at different time periods (24, 48, 72 and 96 h) after transfection of miR‑
519d inhibitor and Smad7 shRNA independently or simultaneously compared with NC group (*P < 0.05). c Flow cytometrical analysis of cell cycle 
distribution was conducted in the indicated groups (*P < 0.05)
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Fig. 6 Depletion of Smad7 restored the migration and invasion of cervical cancer cells under miR‑519d inhibition. a Transwell assay was performed 
to determine the migration capacity of HeLa and SiHa cells after transfection of miR‑519d inhibitor and Smad7 shRNA independently or simultane‑
ously compared with NC group. b, c Statistical analysis of the number of migrated cells in the indicated groups (*P < 0.05). d Matrigel transwell 
assay was performed to determine the invasion capacity of HeLa and SiHa cells after transfection of miR‑519d inhibitor and Smad7 shRNA inde‑
pendently or simultaneously compared with NC group. e, f Quantitative analysis of the number of cells invading through matrigel in the indicated 
groups (*P < 0.05)
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affect miR-519d’s anti-apoptotic function in SiHa cells. 
The detailed involvement of miR-519d in TGF-β signal-
ing transduction and related metastatic pathways would 
be the subject of our future investigation.
In summary, our current study showed that miR-
519d-mediated downregulation of Smad7 might con-
tribute to cervical cancer invasion and metastasis. Using 
cervical cancer cell lines and specimens, we validated 
that miR-519d was associated with Smad7 downregula-
tion and tumor metastasis in cervical cancer. Our find-
ings implicated that targeting miR-519d expression might 
be a valuable approach to prevent the metastasis and 
chemoresistance of cervical cancer.
Clinical practice points
Recent investigations indicated that cervical cancer 
development and progression involved dysregulated 
expression of various microRNAs. In this study, we for 
the first time identified that miR-519d, a miRNA that has 
been implicated in liver, breast and gastric carcinogene-
sis, was significantly upregulated in cervical cancer speci-
mens, compared with non-tumorous cervical tissues. 
Additionally, we found that miR-519d directly targeted 
the mRNA of Smad7 to mediate the decay of Smad7 
mRNA, thus facilitating the metastasis of cervical can-
cer. Using cervical cancer cell cultures, we showed that 
inhibition of miR-519d markedly impaired the migration 
and invasion of cervical cancer cells in vitro. Our findings 
imply that miR-519d may serve as a valuable indicator 
of cervical cancer metastasis. Furthermore, our results 
support the notion that miRNAs-based target therapy 
may be of potential clinical merit in cervical cancer 
management.
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